Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;268(12):4407-4414.
doi: 10.1007/s00415-021-10709-0. Epub 2021 Jul 21.

Posterior Reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature

Affiliations
Review

Posterior Reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature

Francesco Motolese et al. J Neurol. 2021 Dec.

Abstract

Background: SARS-CoV-2 infection has been associated with various neurological manifestations. Since patients affected by SARS-CoV-2 infection present coagulation and immune system dysregulation, ischemic or haemorragic stroke is not uncommon, irrespective of respiratory distress. However, the occurrence of focal neurological deficits together with other symptoms like headache, cortical blindness, seizure and altered mental status should prompt the diagnosis of Posterior Reversible Encephalopathy Syndrome (PRES). Antithrombotic treatment, the alteration of endothelial function, and coagulopathy due to COVID-19 and PRES leading to the breakdown of blood-brain barrier may then contribute to the occurrence of a brain haemorrhage.

Methods: We describe the case of a COVID-19 patient who developed bilateral occipital lobe haemorrhages suggestive of haemorrhagic PRES. We then reviewed the available literature about haemorrhagic evolution of PRES in COVID-19.

Results: We describe the clinical and radiological features of five COVID-19 patients who developed haemorrhagic PRES.

Conclusions: Coagulopathy and endothelial dysfunction resulting from the massive release of cytokines during the host immune response may be key factors in the pathogenesis of COVID-19-related PRES. Antithrombotic therapy and the leakage of the blood-brain barrier can subsequently increase the risk of haemorrhagic transformation of the lesioned brain tissue. A prompt diagnosis of PRES is mandatory, since the timely interruption/reversal of antithrombotic therapy may be a key determinant for a good prognosis.

Keywords: COVID-19; Haemorrhage; PRES; Posterior Reversible Encephalopathy Syndrome; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Dr. Francesco Motolese reports no disclosures; Dr. Mario Ferrante reports no disclosures; Dr. Mariagrazia Rossi reports no disclosures; Dr. Alessandro Magliozzi reports no disclosures; Dr. Martina Sbarra reports no disclosures; Dr. Francesca Ursini reports no disclosures; Dr. Massimo Marano reports no disclosures; Dr. Fioravante Capone reports no disclosures; Dr. Francesco Travaglino reports no disclosures; Dr. Raffaele Antonelli Incalzi reports no disclosures; Dr. Vincenzo Di Lazzaro reports no disclosures; Dr. Fabio Pilato reports no disclosures.

Figures

Fig. 1
Fig. 1
Intraparenchymal hemorrhage with occipital pattern in our patient, at the onset (A), after 4 h (B), after 2 days (C), after 7 days (D), and after 20 days (E). Axial CT scan (A) demonstrates bilateral occipital lobes hematomas with surrounding vasogenic edema. Vascular malformations were not detected on CT angiography (not shown). After 4 h (B) and 2 days (C), axial CT scans show an increase of hematomas volume, especially in the right occipital lobe with a slight mass effect on the right lateral ventricle. After 7 days (D) and 20 days (E) axial CT scans show a progressive decrease in the density and size of hematomas, as for the physiological evolution
Fig. 2
Fig. 2
Different factors contribute to the hemorrhagic evolution of PRES in COVID-19 patients. The reduction in cerebral blood perfusion may be due to the release of vasoactive and proinflammatory molecules in response to COVID-19-related immune activation (round panel). The hypoperfusion determines the breakdown of blood–brain barrier (panel A) that together with antithrombotic treatment (panel B)—a mainstay of SARS-CoV-2 infection therapy—endothelial dysfunction (panel C) and coagulopathy (panel D)—both related to the immune response—contribute to the development of hemorrhage

References

    1. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. doi: 10.1016/S1474-4422(20)30221-0. - DOI - PMC - PubMed
    1. Dono F, Nucera B, Lanzone J, et al. Status epilepticus and COVID-19: a systematic review. Epilepsy Behav. 2021;118:107887. doi: 10.1016/j.yebeh.2021.107887. - DOI - PMC - PubMed
    1. Aghagoli G, Gallo Marin B, Katchur NJ, et al. Neurological involvement in COVID-19 and potential mechanisms: a review. Neurocrit Care. 2020 doi: 10.1007/s12028-020-01049-4. - DOI - PMC - PubMed
    1. Lee M-H, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 2021;384:481–483. doi: 10.1056/NEJMc2033369. - DOI - PMC - PubMed
    1. Fifi JT, Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol. 2020;19:713–715. doi: 10.1016/S1474-4422(20)30272-6. - DOI - PMC - PubMed

MeSH terms